INTRODUCTION
The coincidence of prostate and bladder cancer occurring together in the same individual is considered common. One factor to be considered is the likelihood of diagnostic bias when the presence of one genitourinary cancer leads to a more detailed clinical and pathological examination, resulting in the incidental diagnosis of another genitourinary cancer. Singh et al. [1] evaluated the risk of prostate cancer as a second malignancy in patients diagnosed with bladder cancer after adjusting for possible diagnostic and treatment biases. The standardized incidence ratio (actual number of cases in a population at a given time to the number that would be expected based on the cancer rates in the same area) of prostate cancer in patients with urothelial cancer was significantly increased. The same ratio was not increased for other malignancies.
The high coincidence of prostate and bladder cancers occurring together might be also explained by a common carcinogenic pathway. Tumour-suppressor genes might be crucial in the development of both [2] . Amara et al. [3] showed by immunohistochemical analysis that prostate stem-cell antigen is overexpressed in most TCCs. Despite these findings, the model for a common carcinogenic pathway remains to be confirmed.
ADENOCARCINOMA OF THE PROSTATE: ITS BURDEN IN CYSTOPROSTATECTOMY SPECIMENS
As recently addressed by Saad et al. [4] , cystoprostatectomy specimens provide a unique chance to define the features of silent adenocarcinoma of the prostate. The variability of its frequency can be explained in the first instance by the sampling approach adopted to process the prostate. When slices are too thick, small foci of cancer might remain undetected because they remain 'buried' . The advantage of complete sampling over partial sampling is that small foci of cancer are seen more frequently and cancer features, such extraprostatic extension and positive margins, are more accurately evaluated. Using the technique of McNeal et al. [5] , with slices taken every 2.5 mm from the base to the apex of the gland, a high incidence of prostate cancer can found. Ruffion et al. [6] detected an incidental prostate cancer in 51% of their samples. Similar results were obtained by others with serial step-sections taken at 2-3 mm intervals [7, 8] . Winkler et al. [9] reported the highest detection rate so far (60%) by using 2 mm sections. Nevertheless, although using the same technique, Cindolo et al. [10] reported much lower rates (12.6%), as also did Saad et al. [4] . However, there is a similar wide variability when using a pathological protocol
with 5-mm sections. The detection rate increased to 42% in the study by Montironi et al. [8] , whereas it was surprisingly low (4%) in a recent report from a Taiwanese group [11] . This latter result might be influenced by the lower incidence of prostate cancer in Asian countries. Some studies do not include a description of the applied histopathological evaluation [12] .
CLINICAL SIGNIFICANCE OF AN INCIDENTALLY DISCOVERED PROSTATE CANCER
Stamey et al. [13] discovered unsuspected prostate cancer in 40% of a group of cystoprostatectomy specimens. Reasoning that according to epidemiological data only 8% of prostate cancers are clinically apparent, and that these must be the largest, they took 8% of the largest tumours identified in their series (0.5-6.1 mL) and concluded that any tumour of > 0.5 mL must be clinically significant. With the additional inclusion of any poorly differentiated Gleason 4 or 5 cancer, the 0.5 mL size criteria for a 'clinically significant' tumour has gained wide recognition.
Authors attempted to incorporate PSA levels into predictive models of tumour significance. However, Winkler et al. [9] found a weak correlation between PSA levels and tumour volume, and no difference between median PSA values for patients with and without prostate cancer.
Revelo et al. [7] reported a 41% rate of unsuspected prostate adenocarcinoma, only 48% of these being considered clinically significant. The presence of clinically significant prostate cancer in the study by Barbisan et al. [14] was much higher (81%) than previously reported.
A few non-morphological studies have indicated that incidental cancer is different from clinical cancer in terms of marker expression. In particular, it has cell features of less aggressiveness than clinically detected cancers [15] .
PATIENTS WITH CONCOMITANT PROSTATE AND BLADDER CANCER, AND THEIR FATE
Androulakakis et al. [16] initially suggested that the prognosis in these patients appears to be related to the characteristics of each tumour, separately. Konski et al. [17] reported that most of the patients presented with an early stage of one malignancy and an advanced stage of the other. In their experience, patients presenting with prostate cancer had a better 5-year survival rate (50%) than those presenting with bladder cancer (32%). The most significant prognostic factor was the stage of the bladder cancer.
More recently, Delongchamps et al. [18] reported on 141 patients with invasive bladder cancer, mostly of an advanced tumour stage; 20 (14%) had incidental prostate cancer. Ten patients died from bladder cancer after a median interval of 13 months. The poor survival rate was due to the advanced stage of the bladder tumours seen in the most patients.
Despite a limited amount and profile of available data, it can be concluded that the outcome of patients with incidentally discovered prostate cancer after cystoprostatectomy depends on the prognosis of the bladder tumour.
HOW DOES PSA WORK IN THESE CASES?
Winkler et al. [9] found a statistically significantly higher PSA level in those with incidental prostate cancer, but in the study by Ruffion et al. [6] the mean PSA level in the prostate cancer group was 2.84 ng/mL, which was similar to that in the group without prostate cancer (2.19 ng/mL). The authors could not find a plasma PSA threshold beneath which there was a < 5% association with prostate cancer. More recently, Rocco et al. [19] concluded that PSA levels in their series did not correlate either with the overall risk of prostate cancer or with the risk of clinically significant disease. Saad et al. [4] found no significant correlation between preoperative PSA levels and the presence of adenocarcinoma, the Gleason score or prostatic tumour stage.
Based on the available data, for those who are candidates for prostate-sparing surgery, it seems reasonable to include a routine prostate biopsy in the standard preoperative evaluation, even in men with a normal DRE and PSA levels.
UROTHELIAL PROSTATE CANCER: ITS INCIDENCE AND PROGNOSTIC SIGNIFICANCE
Reports of prostatic urethral involvement at the time of radical cystectomy are mostly retrospective and lack careful pathological assessment of the prostate. Thus, it is likely that the true incidence of involvement with urothelial carcinoma is under-reported. However, the incidence of prostatic urethral involvement approaches 50% in series in which there is a detailed pathological assessment of the prostate [20] .
In a prospective pathological assessment of 121 consecutive cystoprostatectomy specimens analysed by whole mounts, Revelo et al. [7] found urothelial carcinoma involving the prostatic urethra in 48% of cases, 33% of them having apical involvement. All prostates with prostatic apical involvement through urothelial carcinoma uniformly had involvement of more proximal portions of the prostate. These results support the concept of standard cystoprostatectomy.
Retrospective studies have suggested that multifocal bladder tumours, carcinoma in situ (CIS) in the bladder and bladder tumour location in the bladder neck are independent risk factors for prostatic urothelial carcinoma in men undergoing radical cystectomy [20] .
Interestingly, Pettus et al. [21] found that bladder tumours at or below the trigone and CIS in the bladder were associated with prostatic involvement. However, the absence of one or both of these factors was not adequate to identify the entire population of patients without prostatic urothelial tumour.
In this respect, limited biopsies of the prostate urothelium are not adequate to identify prostatic urothelial cancer. Donat et al. [22] took a transurethral biopsy of the prostatic urethra in 246 men undergoing radical cystectomy. The sensitivity of transurethral biopsy for prostatic stromal invasion was 53% and the specificity was 77%, for a positive predictive value of 45% and a negative predictive value of 82%.
Prostatic involvement in urothelial bladder cancer is considered to be an advanced disease. The TNM classification categorises prostate involvement as stage pT4a. This classification does not differentiate contiguous (transmural invasion of the bladder tumour) and non-contiguous (tumour arising in the prostatic urethra) involvement, which are distinct clinicopathological entities with a dissimilar prognosis. In the report by Ayyathurai et al. [23] there was no statistically significant survival difference between those with contiguous and non-contiguous stromal involvement. This emphasizes that the depth of invasion in the prostate, rather than the mode of invasion, affects the outcome. Prostatic stromal involvement, which reflects the depth of invasion, is the most important prognostic factor and the international consensus committee on bladder cancer concluded that the TNM classification of urothelial bladder cancer defines pT4a as prostatic stromal invasion [24] .
CONCLUSIONS
Incidental prostate adenocarcinoma has a variable incidence in cystectomy specimens. Its clinical significance remains questionable, as the outcome of patients depends on the prognosis of the bladder tumour. For those candidates for prostate-sparing surgery, it seems reasonable to include a routine prostate biopsy in the standard preoperative evaluation. Even if it is likely that its true incidence is under-reported, urothelial involvement of the prostate in cystoprostatectomy specimens is common. Multifocal bladder tumours, CIS in the bladder and bladder tumour in the bladder neck are independent risk factors for prostatic urothelial carcinoma. The most important finding in predicting prognosis is the depth of invasion, as reflected by stromal involvement, and not the route of invasion.
